| Overview |
| bsm-54127r-cy3-100ul |
| TXNIP Recombinant Antibody, Cy3 Conjugated |
| WB, IF |
| Human, Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| Synthetic peptide within human TXNIP aa 50-150 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10628 |
| Q9H3M7 |
| Thioredoxin-interacting protein; Thioredoxin-binding protein 2; Vitamin D3 up-regulated protein 1; TXNIP; VDUP1; THIF; ARRDC6; HHCPA78; EST01027. |
| May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells. Acts as a suppressor of tumor cell growth. Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1). |
| Application Dilution |
| WB |
1:300-5000 |
| IF |
|
Powered by Bioz